• Team Archbow

How Cell and Gene Therapy Companies Can Adapt in an Evolving Commercial Landscape

How Cell and Gene Therapy Companies Can Adapt in an Evolving Commercial Landscape

Three changes manufacturers should consider in the wake of COVID-19

Full article published on

For Cell and Gene Therapy (CGT) manufacturers, the strategies for bringing these life-changing treatments to market were never going to be particularly simple. However, the addition of the COVID-19 pandemic has further strained regulators, clinical trial recruitment, the global supply chain, and sites of care, adding commercial complications where they are not needed nor welcomed.

These extra hurdles may sound overwhelming, but challenges and opportunities often go hand-in-hand. Companies willing to reassess and pivot strategically may realize unforeseen commercial advantages.

As Archbow team member, Katie Rapp, writes in Pharmaceutical Executive, CGT manufacturers can make changes now, regardless of the pre-clinical or clinical trial phase, that will better prepare products for commercial success. Read the full article here.


Archbow Consulting helps pharmaceutical and biotech companies in the USA and Europe design, build, and optimize product distribution and patient access strategies. Archbow was founded by industry veterans to meet a need in the marketplace for consulting options that offer diverse real-world experience, are able to leverage deep connections across the industry, and can also provide actionable strategic guidance. We invite you to learn more about our team, services, and clients’ success, and connect with us via email, LinkedIn, Twitter or subscribing to this blog which you can do below.